This site requires a more recent version of Adobe Flash Player to function properly.
Go here to get Flash.
Trefis's graphical modelling tools require Flash, but here's a preview of some of the content you'll see once
Flash is enabled:
Investment Overview for Rite Aid (NYSE:RAD)
Rite Aid's share of retail prescriptions filled in the US: We currently forecast Rite Aid' share of the total prescriptions filled in the U.S. to gradually increase to 8% as it replaces the under performing stores with new ones at better locations and the popularity of its Wellness store format rises. There could be a 10% downside (approximately) to the Trefis price estimate if Rite Aid's share of retail prescriptions remain constant over our forecast horizon.
OTC Drugs and Other Merchandise Revenue per Square Foot of retail drugstore space: We currently forecast the revenue from OTC Drugs and Other Merchandise per Square Foot of retail space to increase from $144 in 2014 to $167 by the end of our forecast period. There could be a 10% downside if this figure remains constant over our forecast horizon.
Rite Aid is the third largest drugstore chain in the US, having stores at 4,570 locations across the U.S. It sells both prescription and non-prescription drugs as well as other retail merchandise(cosmetics, convenience foods etc.).
Prescription drug sales are the biggest source of value for Rite Aid, accounting for close to two-thirds of its total value.
Large drugstore network
With a total of 4,570 stores, Rite Aid has the third largest network of retail drugstores in the U.S.
Prescription drugs is the most important division
Prescription drugs sales is the main revenue source for Rite Aid and accounts for around two-thirds of the company's stock value.
High debt burden
Rite Aid has steadily and consistently improved its front end same-store sales over the last eight quarters and has been narrowing its losses. The sustained performance improvement has been aided by the Wellness loyalty program, store upgrades and the closure of highly under-performing stores. The company reported its first profitable quarter in Q3 FY 2013 and has been able to reduce debt to a certain extent. While the recent acquisition of EnvisionRx (in February 2015) has added to the company's debt, cash flow generated from it is expected to offset this increase in the long term.
Increasing demand and utilization of prescription drugs in the U.S.
The U.S. has an aging population, and as older people contribute to a larger proportion of expenditure on drugs (people above 60 spend on average 2-3 times more than those below 40), this will lead to an increase in the prescription drugs market in the U.S. The 2010 U.S. health reform legislation is also expected to increase prescription drug sales, as over 30 million uninsured Americans will gain coverage and the U.S. government will accordingly increase outlay on prescription drugs. This will be driven by an expansion of Medicaid and Medicare Part D plans.
Wellness+ card-based loyalty program
Rite Aid rolled out its Wellness+ card-based loyalty program in April 2010 making substantial investments in 2011. It provides benefits to cardholders based on the accumulation of points for front end and prescription purchases.
As of March 1, 2014, the program had over 25 million active members, accounting for 79% of front end sales and 68% of prescriptions filled. Wellness+ members have higher basket sizes than non-members and a much higher rate of prescription retention. The wellness+ program has helped increase Rite Aid's sales since its launch.
Efforts to increase share in the U.S. retail prescription market
Rite Aid plans to gradually increase the amount of capital allocated to the purchase of prescription files. Historically, it raised the amount of investment significantly, from $24.2 million in 2011 to $75.0 million in 2012. Later in 2014, the company increased the amount of capital spent to $87.4 million, up from $67.1 million in fiscal 2013.
Sales of generic drugs to positively impact margins
Generic drugs offer approximately 50% higher gross margins compared to branded drugs. The total generic dispensing rate, which factors the percentage of generic drugs in a consumer’s prescription, grew to 78.5% in 2012, from 74.1% and 71.5% in 2011 and 2010, respectively. Over the past few years, the share of generics in a typical consumer’s prescription has steadily increased. But, the rate at which their use increased has slowed down, owing to fewer generic drugs being launched in 2014 compared to the year before. Nevertheless, another $47.5 billion in sales (in the prior year) will come under threat of patent expiry in 2015, opening them to competition from generic drugs. With the expansion of generic drug sales in the U.S. (even if the pace is expected to slow down), each script will bring an incremental $5-7 in profits, allowing up to 10% growth in EBIT margins.
However, some of these margin benefits have been partially offset by a combination of increasing generic prices and flat reimbursement rates. As retailers received a smaller share of a drug's price as reimbursement from payers, they accumulated heavy losses.
Store remodeling and closure of under-performing stores
The number of RiteAid retail drugstores in the U.S. declined from over 5,000 in 2008 to 4,623 in 2012 as Rite Aid started liquidating its unprofitable stores. By the end of 2014, the number reached 4,570. We expect the trend to continue over the next couple of years as Rite Aid continues to evaluate store performances and closes under-performing stores.
In order to improve the same-store-sales, Rite Aid is remodeling its stores. It has remodeled approximately 800 stores to its new Wellness Format, which has a unique merchandising display and targets remodeling of its entire chain over the next 5 years.
Segmentation strategy: Wellness, Save-a-Lot and Value Format stores
Rite Aid is building a segmentation strategy, experimenting with different store formats that are better tailored to meet the needs of the particular market that the store is in. They include Wellness, Save-a-Lot and Value formats.
During fiscal 2011, it entered into a ten store pilot with Save-a-Lot, a subsidiary of SUPERVALU, Inc. The co-branded Save-A-Lot/Rite Aid pilot stores have a full grocery shop including meat, produce, dairy, traditional drugstore offerings and a full service pharmacy. The format has presented encouraging results on the front end sales in its pilot phase with doubling or tripling of revenues. Rite Aid is likely to expand this format in the future.
Rite Aid has also piloted a value store format with lower front end prices and more focused front end sku selection to better compete in markets where pricing is the main competitive differentiator.
Revenues are also expected to improve in the Wellness format stores with remodeled stores, an expanded selection of organic foods, personal care products and homeopathic medicines. These stores will also have expanded clinical pharmacy services, including diabetes care specialists and medication therapy management experts.
Expansion of immunization services
In 2011, Rite Aid tripled the amount of immunizing pharmacists to 7,400, expanded its immunization services to over 3,000 stores and administered 675,000 flu shots. In 2014, the company administered more than 2.8 million flu shots. Immunization will continue to be a key focus area for the company going forward.
Increasing penetration of private brands
In 2011, Rite Aid began the roll-out of a new private brand architecture, consolidating them in three separate tiers and improving private brand penetration over the previous year. The company has already converted 1000 SKUs in 2011, 2,900 in 2012 and followed up by enhancing the package designs of seasonal private brand items in 2013. These are expected to improve same-store-sales and improve gross margins. Rite Aid brand penetration at the end of fiscal 2014 was 18.2%.
How Does Trefis Modelling Work?
How do we get the historical numbers for this chart?
Trefis has a team of in-house Analysts who gather historical data from company filings and other verifiable sources. When historicals are available, we explain how we got them at the bottom of the Trefis analysis section below.
Who came up with the Trefis forecast for future years?
The Trefis team of in-house Analysts considers a variety of factors when projecting any forecast. The rationale for our projections is explained in the Trefis analysis section below.
How does my dragging the trendline on the chart impact the stock price?
- We use forecasts for business drivers to calculate forecasted Revenues and Profits for each division of the company.
- We then use forecasted Profits in a Discounted Cash Flow (DCF) model to obtain the Price Estimate for the company.
See more on: DCF Methodology
View All Help Topics